Piper Sandler on Amgen (AMGN): 'Repatha Remains a Standout'

March 25, 2025 8:16 AM EDT Send to a Friend
Piper Sandler analyst David Amsellem reiterated an Overweight rating and $329.00 price target on Amgen (NASDAQ: AMGN).The analyst commented: "Monthly ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login